IMUX stock forecast 2025 has drawn attention from momentum traders, who leverage breakout patterns around earnings or pipeline updates to capitalize on sector sentiment shifts. We can report that insiders do own shares in Immunic, Inc.. In their own names, insiders own US$1.4m worth of stock in the US$114m company. Some would say this shows alignment of interests between shareholders and the board, though we generally prefer to see bigger insider holdings. But it might be worth checking if those insiders have been selling. We have seen 22 institutional investors add shares of $IMUX stock to their portfolio, and 36 decrease their positions in their most recent quarter. IMUX’s 2025 trajectory will be influenced by biotech ETF flows; if funds like IBB increase allocations post-positive data, liquidity could spike, supporting sustained price levels above resistance zones.
